Topical pharmaceutical compositions

Patent metadata

Field	Value
Publication number	US-9907807-B2
Application number	US-201514883898-A
Country	US
Kind code	B2
Filing date	Oct 15, 2015
Priority date	May 26, 2010
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.

First claim

The invention claimed is:

1. A topical pharmaceutical composition comprising, based on the total weight of the composition:
a) 0.08 to 0.12 wt. % of mometasone furoate,
b) 8 to 13 wt. % of hexylene glycol,
c) 26 to 34 wt. % of water, and
d1) 35 to 48 wt. % of petroleum hydrocarbons chosen from liquid paraffin, white soft paraffin and mixtures thereof,
d2) 7 to 10 wt. % of C 6 -C 24 fatty alcohols chosen from lauryl alcohol, miristyl alcohol, palmityl alcohol, stearyl alcohol, oleyl alcohol and mixtures thereof, and
d3) 0.5 to 3 wt. % of glycerol,
wherein the mometasone furoate is suspended in the composition.

2. The composition according to claim 1 , wherein the composition further comprises anti-irritants agents, antioxidants agents, buffering agents, chelating agents, emollients, penetration enhancing agents, preservative agents, solubilizing agents, thickening agents, wetting agents or mixtures thereof.

3. The composition according to claim 1 , wherein the composition has a pH value in the range of 3.0 to 6.0.

4. The composition according to claim 1 , wherein the composition is formulated in the form of a cream.

5. A method for treating a subject afflicted with psoriasis or atopic dermatitis, comprising applying to the affected area of skin of said subject an effective amount of the composition of claim 1 .

6. The composition according to claim 1 , wherein the total amount of a) mometasone furoate is 0.1 wt. %, based on the total weight of the composition.

Assignees

• Almirall Sa

Inventors

• Evers Fritjof
• Mallwitz Henning
• Wessel Ricarda
• Willers Christoph

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61P17/04

  Antipruritics · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title